Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyrimidine biosynthesis enzymes in protozoa are a group of enzymes responsible for the de novo synthesis of pyrimidine nucleotides, which are essential building blocks for DNA and RNA. This pathway is crucial for the survival and proliferation of many parasitic protozoa, including species such as Plasmodium (malaria), Trypanosoma, Leishmania, Toxoplasma gondii, and others. Key enzymes include carbamoyl phosphate synthetase, aspartate transcarbamoylase, dihydroorotase, dihydroorotate dehydrogenase, orotate phosphoribosyltransferase, and OMP decarboxylase. These enzymes are validated drug targets due to structural/kinetic differences compared to mammalian homologs, offering the potential for selective inhibition and antiparasitic drug development.
Inhibition of pyrimidine biosynthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyrimidine Biosynthesis Enzymes (Protozoa).